tradingkey.logo
搜索

Charles River Laboratories International Inc

CRL
添加自选
234.800USD
-5.630-2.34%
收盘 07-29 16:00美东报价延迟15分钟
11.31B总市值
亏损市盈率 TTM

Charles River Laboratories International Inc

234.800
-5.630-2.34%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-2.34%

5天

+7.36%

1月

+4.09%

6月

+10.92%

今年开始到现在

+17.71%

1年

+31.58%

关键数据
238.780今开
242.400最高
1.05M成交量
亏损市盈率 TTM
18.79市盈率动
--股息TTM
2.19%换手率
240.430昨收
234.180最低
144.93M成交额
1098.34市盈率静
3.85市净率
0.00%股息率 TTM
-2.39%ROA
228.88052周最高
1.29量比
10.30M净利润
48.17M总股本
-3.7180每股收益TTM
1.46Beta
-6.02%ROE
132.58352周最低
3.42%振幅
30.90%毛利率
11.31B总市值
2.30回报/风险
2.62%风险率

操作建议

Charles River Laboratories International Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名20/384位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价231.44。中期看,股价处于上升通道。近一个月,市场表现一般,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Charles River Laboratories International Inc评分

相关信息

行业排名
20 / 384
全市场排名
66 / 4277
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Charles River Laboratories International Inc亮点

亮点风险
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
业绩转亏
公司业绩转亏,最新年度亏损美元
估值合理
公司最新PE估值-63.15,处于3年历史合理位
机构减仓
最新机构持股56.13M股,环比减少12.43%
约翰·罗杰斯持仓
明星投资者约翰·罗杰斯持仓,最新持仓市值1.51M

分析师目标

根据 19 位分析师
买入
评级
231.445
目标均价
+3.19%
涨幅空间

收益预测

分析师评级

根据 19 位分析师
买入
评级
231.445
目标均价
+3.19%
涨幅空间
强力买入
买入
持有
卖出
强力卖出

同行比较

496
总数
6
中位数
7
平均值
公司名称
评级分布
分析师数
Charles River Laboratories International Inc
CRL
19
百济神州
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
艾昆纬
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99

技术指标

技术指标
卖出(2)
中性(2)
买入(3)
指标
数值
方向
MACD(12,26,9)
-1.667
中性
RSI(14)
62.208
中性
STOCH(KDJ)(9,3,3)
70.825
买入
ATR(14)
9.245
高波动
CCI(14)
124.935
买入
Williams %R
27.037
买入
TRIX(12,20)
0.480
卖出
StochRSI(14)
45.092
卖出
移动平均线
卖出(0)
中性(0)
买入(6)
指标
数值
方向
MA5
231.080
买入
MA10
226.671
买入
MA20
228.338
买入
MA50
201.225
买入
MA100
185.123
买入
MA200
186.564
买入

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Charles River Laboratories International Inc简介

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
公司代码CRL
公司Charles River Laboratories International Inc
CEOFoster (James C)
网址https://www.criver.com/

公司股东

持股股东
持股股东
占比
Vanguard Capital Management, LLC
6.65%
BlackRock Institutional Trust Company, N.A.
5.97%
Vanguard Portfolio Management, LLC
4.76%
Allspring Global Investments, LLC
4.14%
State Street Investment Management (US)
3.89%
其他
74.59%

常见问题

Charles River Laboratories International Inc(CRL)的当前股价是多少?

Charles River Laboratories International Inc(CRL)的当前股价是 234.80。

Charles River Laboratories International Inc的股票代码是什么?

Charles River Laboratories International Inc的股票代码是CRL。

Charles River Laboratories International Inc股票的52周最高点是多少?

Charles River Laboratories International Inc股票的52周最高点是228.88。

Charles River Laboratories International Inc股票的52周最低点是多少?

Charles River Laboratories International Inc股票的52周最低点是132.58。

Charles River Laboratories International Inc的市值是多少?

Charles River Laboratories International Inc的市值是11.31B。

现在Charles River Laboratories International Inc(CRL)的股票是买入、持有还是卖出?

根据分析师评级,Charles River Laboratories International Inc(CRL)的总体评级为买入,目标价格为231.44。

Charles River Laboratories International Inc(CRL)股票的每股收益(EPS TTM)是多少

Charles River Laboratories International Inc(CRL)股票的每股收益(EPS TTM)是-2.91。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有